Otonomy

Otonomy Debt

Delisted

The Debt of Otonomy (OTIC) as of Nov 10, 2026 is 16.30 M USD. In the previous year, Debt was 15.20 M USD — a change of 7.21% (higher).

Debt

16.30 MUSD

YoY

7.21%

Last updated:

In 2021, Otonomy's total debt was 16.30 M USD, a 7.21% change from the 15.20 M USD total debt recorded in the previous year.

The Otonomy Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2014
0.00 USD
Jan 1, 2015
0.00 USD
Jan 1, 2016
0.00 USD
Jan 1, 2017
0.00 USD
Jan 1, 2018
14.80 M USD
Jan 1, 2019
15.10 M USD
Jan 1, 2020
15.20 M USD
Jan 1, 2021
16.30 M USD
The Otonomy Debt history
YEARDebtYoY
16.30 MUSD+7.21%
15.20 MUSD+0.66%
15.10 MUSD+2.03%
14.80 MUSD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Otonomy Stock analysis

What does Otonomy do? Otonomy Inc is a biopharmaceutical company focused on developing innovative therapies for inner ear disorders. The company was founded in 2008 in San Diego, California and has since made significant advancements to bring its products to market. Otonomy's business model is based on identifying unmet medical needs in the field of otolaryngology. The company develops and markets FDA-approved ear medications that are designed in new and innovative ways to improve the treatment of hearing and balance disorders. The different divisions of Otonomy include clinical research, product development, manufacturing, and distribution. The company has an experienced team of scientists, engineers, clinical researchers, and managers who work closely together to develop and bring Otonomy's pipeline of drug candidates to market. The company has launched a number of products targeting the needs of patients with inner ear disorders. For example, the medication Otiprio was developed to treat otitis media, an inflammation of the middle ear. Otiprio is delivered directly into the ear during a minor surgery, where it quickly acts to eliminate the inflammation. Another one of Otonomy's products is Otividex, a medication developed to treat patients with Meniere's disease. This condition is a rare inner ear disorder that causes dizziness, tinnitus, and hearing loss. Otividex is also delivered directly into the ear and has shown to alleviate the dizziness symptoms and improve hearing. In recent years, Otonomy has also developed a new technology called OTO-413, which aims to improve hearing by regenerating damaged hair cells in the inner ear. The company has successfully conducted clinical trials with OTO-413 and plans to further explore and develop the technology. Otonomy has also formed partnerships with other companies and organizations in recent years to further develop its technologies and bring new products to market. For example, the company has entered into a collaboration agreement with Merck to develop new therapies for inner ear disorders. Otonomy also collaborates with a number of academic institutions and research facilities to further explore and develop the potential of its technologies. Overall, Otonomy Inc is an innovative and dynamic company dedicated to developing new therapies for inner ear disorders. With a strong pipeline of drug candidates and a dedicated group of scientists and researchers, the company is well positioned to make significant advancements in the treatment of hearing and balance disorders in the coming years. Otonomy is one of the most popular companies on Eulerpool.

Debt Details

Understanding Otonomy's Debt Structure

Otonomy's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Otonomy's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Otonomy’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Otonomy’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Otonomy stock

Debt of Otonomy is 16.30 M USD in 2021.

Debt of Otonomy changed from 15.20 M USD to 16.30 M USD, representing a 7.21% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt Otonomy since 2006 – with annual values, charts, and detailed analysis.

Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Otonomy historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Otonomy

All Key Metrics — Otonomy